|Creating the next generation of cancer treatments
January 9, 2014
Arno Therapeutics to Present at Biotech Showcase 2014
CEO Glenn Mattes to Present Recent Accomplishments and Development Strategy at Leading Investor Conference for Small-Cap Healthcare Companies
FLEMINGTON, NJ - January 9, 2014 - Arno Therapeutics, Inc. (OTCQB: ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that Chief Executive Officer Glenn Mattes is scheduled to present at Biotech Showcase™ 2014, taking place January 13-15, 2014 in San Francisco, Calif.
Mr. Mattes will present on Wednesday, January 15, 2014 at 10:00 a.m. PST to attending investors, pharmaceutical and healthcare executives. During his presentation, Mr. Mattes will discuss Arno's business and growth strategy, clinical developments of its lead oncology candidate, onapristone, and accompanying companion diagnostic. Mr. Mattes will also discuss recent milestones, including the start of Arno's Phase I clinical trial for onapristone in progesterone receptor positive tumors.
Details of the presentation are as follows:
Date: Wednesday, January 15, 2014
Time: 10:00 a.m. PST
Place: Parc 55 Wyndham San Francisco, Union Square
Track: C - Mission II (3rd Floor)
Investors and analysts interested in scheduling a 1-on-1 meeting with the Arno management team during the conference may do so by contacting Lee Roth of The Ruth Group at email@example.com.
About Arno Therapeutics
Arno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer. Arno has exclusive worldwide rights to develop and market three innovative anti-cancer product candidates. These compounds are in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors. For more information about the company, please visit www.arnothera.com.
About Biotech Showcase™ 2014
Biotech Showcase™ is an investor and partnering conference devoted to providing private and small- and mid-cap biotechnology companies an opportunity to present to and meet with investors and biopharmaceutical executives during the course of one of the largest annual healthcare conferences that attracts investors and biopharmaceutical executives from around the world. The 2013 edition showed a substantial increase in the number of presenting companies, as well as significant growth in the number of attendees and one-to-one meetings. The 2013 event featured corporate presentations by 236 public and private biotechnology and life science companies, and drew 1,600 delegates who engaged in 2,500 one-to-one meetings.
Forward-Looking Statements: This press release contains forward-looking statements that involve substantial risks and uncertainties. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These forward-looking statements include, without limitation, statements regarding the timing, progress and anticipated results of the clinical development of onapristone and accompanying companion diagnostic, as well as Arno's strategy, future operations, outlook, milestones, future financial position, future financial results, plans and objectives. We may not actually achieve these plans, intentions or expectations and Arno cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make. Such factors include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of onapristone or any of our other product candidates, our ability to finance the development of our product candidates, regulatory risks, and our reliance on third party researchers and other collaborators. Additional risks are described in the company's Annual Report on Form 10-K for the year ended December 31, 2012. Arno is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
The Ruth Group
Lee Roth (investors)
Kirsten Thomas (media)